Company intelligence / Profile preview

De novo Biotherapeutics

Ownership: Private
Development stage: Preclinical

Overview

A Seoul-based biotech founded in September [2021], developing mRNA-encoded NK cell-engaging antibodies for oncology applications. Their platform aims to overcome manufacturing challenges of protein-based multi-specific antibodies through mRNA/LNP technology.

Modalities: mRNA-encoded antibodiesLipid nanoparticles (LNPs)Multi-specific antibodies
Industry: Biotech

Drug pipeline

5 assets

DNB-101

Preclinical

4 more assets in the full pipeline.

Beyond the preview

Go deeper on De novo Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on De novo Biotherapeutics.